Aerocrine appoints Morten Gunvad as VP Commercial Operations Europe and Asia

Aerocrine appoints Morten Gunvad as VP Commercial Operations Europe and
Asia

SOLNA, Sweden - 15 August 2011 - Aerocrine AB today announced the
appointment of Morten Gunvad as Vice President Commercial Operations
Europe and Asia.  Morten will lead the company's overall sales and
marketing operations outside North America to accelerate sales both in
Aerocrine's direct and distributor markets.

Morten Gunvad brings 17 years of industry experience from senior
commercial leadership roles. Most recently, Morten has served as Vice
President Soft Tissue Implants Europe at Covidien, a $10 billion global
healthcare products leader.

Based in Sweden, Morten will have the responsibility for bringing even
greater focus to Aerocrine's commercial operations in Europe and Asia,
as well as to further develop the company's regional sales and marketing
strategies. He will report directly to Aerocrine's CEO and will serve on
the company's executive management team.

Morten Gunvad said, “Aerocrine has built a great foundation based on
scientific innovation and is bringing a revolutionary new biomarker to
the international market. The company is the global leader supplying
unique products and services that address a significant unmet medical
need in one of the world's most widespread chronic diseases. I am
excited to join Aerocrine and contribute to making the company's
products available to a growing number of patients living with asthma.”

“Aerocrine is commercially active in numerous European and Asian markets
where a significant share of the company's revenues is generated. Morten
Gunvad's extensive practical experience from international
commercialization and strategic development in the life sciences
industry will be an important strengthening of our organization,” says
Paul de Potocki, CEO of Aerocrine. “I am very happy to welcome Morten to
Aerocrine's management team.”

   Asthma is a chronic inflammatory disease of the airways characterized
by symptoms including wheezing and difficulty in breathing. The disease
affects more than 300 million people around the world, of whom a
significant number are children. Aerocrine's founders made the original
discovery that the levels of nitric oxide in exhaled breath, FENO, is
elevated in patients with asthma. This has enabled a quick, effective
and proactive method to measure the underlying inflammation in asthma,
rather than being limited to reactively monitor its negative
consequences in the form of symptoms and reduced lung function. The
method has significant value in connection with diagnosis and choice of
appropriate medication, as well as for the continuous management of
asthma which is aimed at controlling the airway inflammation. Today,
more than four million patient tests have been performed around the
world using Aerocrine's NIOX products.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80